University of Turin-ko ikertzaileekin lankidetzan egindako argitalpenak (17)

2024

  1. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

    Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

  2. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  3. The Functional Neuroimaging of Autobiographical Memory for Happy Events: A Coordinate-Based Meta-Analysis

    Healthcare (Switzerland), Vol. 12, Núm. 7

2023

  1. Surgical Treatment of Nonmineralized Supraspinatus Tendinopathy in Dogs: A Retrospective Long-Term Follow-Up

    Animals, Vol. 13, Núm. 4

2022

  1. Providing Spiritual Care to In-Hospital Patients During COVID-19: A Preliminary European Fact-Finding Study

    Journal of Religion and Health, Vol. 61, Núm. 3, pp. 2212-2232

2021

  1. Haplo-identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT

    American Journal of Hematology, Vol. 96, Núm. 5, pp. 571-579

2020

  1. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 3, pp. 628-639

2019

  1. Retirement Difficulties in Spanish Athletes: The Importance of the Career Path

    Sport, Exercise, and Performance Psychology, Vol. 8, Núm. 4, pp. 387-400

2016

  1. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 6, pp. 471-478

2012

  1. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting

    Therapeutic Drug Monitoring, Vol. 34, Núm. 2, pp. 232-235

2011

  1. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction

    Journal of Infectious Diseases, Vol. 204, Núm. 1, pp. 145-153

  2. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: The ARTEN Trial

    Antiviral Therapy, Vol. 16, Núm. 3, pp. 339-348

  3. The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference

    Journal of Viral Hepatitis, Vol. 18, Núm. SUPPL. 1, pp. 1-16

2010

  1. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations

    AIDS, Vol. 24, Núm. 7, pp. 1064-1066

  2. Population pharmacokinetic modeling of the association between 63396C→T pregnane X receptor polymorphism and unboosted atazanavir clearance

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 12, pp. 5242-5250

2009

  1. When and how to use maraviroc in HIV-infected patients

    AIDS, Vol. 23, Núm. 18, pp. 2377-2385

2005

  1. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations

    AIDS Research and Human Retroviruses, Vol. 21, Núm. 6, pp. 555-559